Majid Momeny

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 6

Top Topics

Histone Deacetylase

Vascular Endothelial Growth Factor

Immune Response

Top Venues

Cellular oncology (Dordrecht)

Science translational medicine

Cell biochemistry and function

Journal of receptor and signal transduction research

This page only lists publications with an associated author ORCID identifier.

Publications

Atieh Pourbagheri-Sigaroodi, Majid Momeny, Nima Rezaei, Fatemeh Fallah, Soroush Sadeghi
Immune landscape of hepatocellular carcinoma: From dysregulation of the immune responses to the potential immunotherapies. Cell biochemistry and function 42 (5) (2024)
Julia P Vainonen, Majid Momeny, Jukka Westermarck
Druggable cancer phosphatases. Science translational medicine 13 (588) (2021)
Mahdieh Mehrpouri, Majid Momeny, Soroush Sadeghi
Synergistic effects of BKM120 and panobinostat on pre-B acute lymphoblastic cells: an emerging perspective for the simultaneous inhibition of PI3K and HDACs. Journal of receptor and signal transduction research (2020)
Majid Momeny, Zivar Alishahi, Haniyeh Eyvani, Fatemeh Esmaeili, Azam Zaghal, Parisa Ghaffari, Javad Tavakkoly-Bazzaz, Kamran Alimoghaddam, Ardeshir Ghavamzadeh, Seyed H Ghaffari
Anti-tumor activity of cediranib, a pan-vascular endothelial growth factor receptor inhibitor, in pancreatic ductal adenocarcinoma cells. Cellular oncology (Dordrecht) 43 (1) (2019)
Majid Momeny, Fatemeh Esmaeili, Sepideh Hamzehlou, Hassan Yousefi, Sepehr Javadikooshesh, Vasimeh Vahdatirad, Zivar Alishahi, Seyedeh H Mousavipak, Davood Bashash, Ahmad R Dehpour, Seyyed M Tavangar, Javad Tavakkoly-Bazzaz, Peiman Haddad, Farzaneh Kordbacheh, Kamran Alimoghaddam, Ardeshir Ghavamzadeh, Seyed H Ghaffari
The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells. Cellular oncology (Dordrecht) 42 (4) (2019)
Otto Kauko, Caitlin M O'Connor, Evgeny Kulesskiy, Jaya Sangodkar, Anna Aakula, Sudeh Izadmehr, Laxman Yetukuri, Bhagwan Yadav, Artur Padzik, Teemu Daniel Laajala, Pekka Haapaniemi, Majid Momeny, Taru Varila, Michael Ohlmeyer, Tero Aittokallio, Krister Wennerberg, Goutham Narla, Jukka Westermarck
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. Science translational medicine 10 (450) (2019)